Epigenetic ‘Priming’ Boosts Cancer Immunotherapy

July 25, 2022 11:11 am

by Will Doss

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, making them more suitable for treatment with immunotherapy, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This could … Read more

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

July 7, 2022 10:30 am

NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.

For Read more

MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

June 5, 2022 9:55 am

by Caroline Hopkins

CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.

The drug, which AstraZeneca licensed from Merck in … Read more

A Sensor Sniffs for Cancer, Using Artificial Intelligence

May 12, 2022 9:51 am

Biomedical engineer Daniel Heller leads the Cancer Nanomedicine Laboratory at MSK. 

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a sensor that can be trained to sniff for cancer, with the help of artificial intelligence.

Although the training … Read more

Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

April 27, 2022 12:40 pm

by Matthew Stenger

In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more

Biomarkers Found for Platinum Resistance in Gynecologic Cancer

November 19, 2021 11:56 am

Blood-based metabolic signatures may predict whether women with ovarian or uterine cancer will respond well to platinum-based chemotherapy, according to a study by researchers in the Department of Gynecology at the Federal University of São Paulo’s Medical School (EPM-UNIFESP) in … Read more

MCW scientists uncover potential therapeutic target and biomarker for ovarian cancerPortfolio Inspiration

November 17, 2021 11:28 am

MEDICAL COLLEGE OF WISCONSIN

The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer

Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more

Repare Therapeutics’ RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology

November 4, 2021 11:09 am

by Alison Kanski

NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.

Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more

3 Points: Numbers Have a Different Meaning for Patients With Cancer

October 21, 2021 12:00 am

by Julie S. Brokaw

A woman with ovarian cancer describes how blood work numbers play a key role for patients with cancer and often dictate their thoughts and worries.

The number three is a special number. As a former math

Read more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

High Tumor Mutational Burden Predicts Immunotherapy Response in Some—but Not All—Cancers

March 16, 2021 6:00 pm

High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology.

The findings suggest that … Read more

Pap Test/Cervical Swab Samples Can Reveal Ovarian Cancer Biomarkers

February 22, 2021 10:00 am

 Sharon Worcester

Residual fixatives from liquid-based Pap tests and cervical swabs contain tumor-specific biomarkers for ovarian cancer, according to an analysis of proteins found in matched biospecimens from a woman with high grade serous ovarian cancer.

The findings suggest … Read more

How Biomarker Testing May Help Women Battling Ovarian Cancer

February 18, 2021 6:00 pm

Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.

By

Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of

Read more

Moffitt Researchers Discover Mechanism that Regulates Anti-Tumor Activity of Immune Cells

February 3, 2021 3:00 am

The study finally paves the way for the use of antibodies different from IgG as immunotherapeutic agents for at least tumors currently resistant to conventional immune checkpoint blockade.

The prognosis of ovarian cancer is poor, with an estimated five-year survival … Read more

Large Genomics Study Points the Way to Future Cancer Clinical Trials

October 14, 2020 11:00 am

By Angus Liu

Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more

Phase I Data of XMT-1536 Supports Continued Development in Ovarian Cancer

September 17, 2020 1:00 pm

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more

PARP Inhibitors Deemed Too Costly For Across-the-Board Frontline Maintenance in Ovarian Cancer

September 11, 2020 8:00 pm

By Leah Lawrence

A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more

How Does Ovarian Cancer Form? A New Study Points to MicroRNA

July 30, 2020 4:00 pm

Although ovarian cancer is the fifth-leading cause of death from cancer in women, scientists don’t have a good handle on how it forms. Now a new study suggests that a microRNA—a molecule made by cells to turn genes on … Read more

Ovarian Cancer Metastasis Study Identifies Important Protein with Potential as Diagnostic Tool and Treatment Option

July 16, 2020 3:00 pm

By Clayton Boldt, Ph.D

Advanced ovarian cancer most commonly metastasizes to the omentum, a layer of fatty tissue that wraps around and protects internal organs in the abdomen, but the reasons for this have not been well-understood. In a new … Read more